Do analysts rate MOR or AXSM?

Axsome Therapeutics has a consensus target price of $267.60, suggesting a potential upside of 27.80%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Axsome Therapeutics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has better valuation & earnings, MOR or AXSM?

Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Axsome Therapeutics $638.50M 17.18 -$183.17M -$3.75 N/A

Do analysts prefer RDY or MOR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate MOR or LNTH?

Lantheus has a consensus target price of $108.11, indicating a potential upside of 7.18%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lantheus 0 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29

Which has better valuation and earnings, MOR or LNTH?

Lantheus has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.36

Is MOR or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to MorphoSys' net margin of -226.79%. Lantheus' return on equity of 28.10% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Lantheus 17.69% 28.10% 14.35%

Do analysts recommend MOR or BLTE?

Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 20.80%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Belite Bio 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is MOR or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Belite Bio's return on equity of -11.84% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Belite Bio N/A -11.84% -11.62%

MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 09/2/2026

Compare

MOR vs. AXSM, RDY, CRNX, LNTH, and BLTE

Should you buy MorphoSys stock or one of its competitors? MorphoSys's main competitors and comparable companies include Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MorphoSys compare to Axsome Therapeutics?

MorphoSys (NASDAQ:MOR) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Axsome Therapeutics has a net margin of -24.68% compared to MorphoSys' net margin of -226.79%. Axsome Therapeutics' return on equity of -265.55% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

In the previous week, Axsome Therapeutics had 20 more articles in the media than MorphoSys. MarketBeat recorded 20 mentions for Axsome Therapeutics and 0 mentions for MorphoSys. Axsome Therapeutics' average media sentiment score of 0.84 beat MorphoSys' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Axsome Therapeutics	Positive

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics has a consensus target price of $267.60, suggesting a potential upside of 27.80%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Axsome Therapeutics	$638.50M	17.18	-$183.17M	-$3.75	N/A

Summary

Axsome Therapeutics beats MorphoSys on 13 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Dr. Reddy's Laboratories had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Dr. Reddy's Laboratories and 0 mentions for MorphoSys. Dr. Reddy's Laboratories' average media sentiment score of 0.59 beat MorphoSys' score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Positive
MorphoSys	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	27.25
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
MorphoSys	-226.79%	-694.31%	-22.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Reddy's Laboratories has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats MorphoSys on 11 of the 14 factors compared between the two stocks.

How does MorphoSys compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and MorphoSys (NASDAQ:MOR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Crinetics Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 16 more articles in the media than MorphoSys. MarketBeat recorded 16 mentions for Crinetics Pharmaceuticals and 0 mentions for MorphoSys. Crinetics Pharmaceuticals' average media sentiment score of 0.86 beat MorphoSys' score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Positive
MorphoSys	Neutral

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential downside of 4.65%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MorphoSys has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

MorphoSys has a net margin of -226.79% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Crinetics Pharmaceuticals beats MorphoSys on 9 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Lantheus?

MorphoSys (NASDAQ:MOR) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.36

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to MorphoSys' net margin of -226.79%. Lantheus' return on equity of 28.10% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Lantheus	17.69%	28.10%	14.35%

Lantheus has a consensus target price of $108.11, indicating a potential upside of 7.18%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Lantheus and 0 mentions for MorphoSys. Lantheus' average media sentiment score of 1.38 beat MorphoSys' score of 0.00 indicating that Lantheus is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Lantheus	Positive

Summary

Lantheus beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Belite Bio?

MorphoSys (NASDAQ:MOR) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Belite Bio's return on equity of -11.84% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio has lower revenue, but higher earnings than MorphoSys. Belite Bio is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 20.80%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Belite Bio and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Belite Bio'saverage media sentiment score.

Company	Overall Sentiment
MorphoSys	Neutral
Belite Bio	Neutral

Summary

Belite Bio beats MorphoSys on 10 of the 14 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.86B	$12.30B	$7.25B	$12.92B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	-5.45	789.77	273.84	25.43
Price / Sales	11.99	956.14	675.54	123.68
Price / Cash	N/A	92.66	76.98	52.08
Price / Book	54.17	12.42	12.90	6.17
Net Income	-$205.35M	$2.83B	$3.48B	$349.24M
7 Day Performance	N/A	2.26%	-0.42%	-1.46%
1 Month Performance	N/A	5.06%	6.41%	2.47%
1 Year Performance	N/A	9.28%	24.92%	15.80%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
AXSM Axsome Therapeutics	4.1812 of 5 stars	$207.15 +0.8%	$267.60 +29.2%	+70.0%	$10.76B	$638.50M	N/A	380	Analyst Forecast
RDY Dr. Reddy's Laboratories	1.7561 of 5 stars	$12.24 -0.8%	N/A	-13.8%	$10.30B	$3.58B	27.82	27,527
CRNX Crinetics Pharmaceuticals	1.5923 of 5 stars	$84.84 0.0%	$81.00 -4.5%	N/A	$9.00B	$7.70M	N/A	210	News Coverage Analyst Forecast
LNTH Lantheus	3.9216 of 5 stars	$100.82 0.0%	$108.11 +7.2%	+82.3%	$6.58B	$1.54B	24.35	1,193	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. AXSM, RDY, CRNX, LNTH, and BLTE

How does MorphoSys compare to Axsome Therapeutics?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Summary

How does MorphoSys compare to Crinetics Pharmaceuticals?

Summary

How does MorphoSys compare to Lantheus?

Summary

How does MorphoSys compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. AXSM, RDY, CRNX, LNTH, and BLTE

How does MorphoSys compare to Axsome Therapeutics?

Is MOR or AXSM more profitable?

Does the media refer more to MOR or AXSM?

Do institutionals & insiders hold more shares of MOR or AXSM?

Do analysts rate MOR or AXSM?

Which has more risk & volatility, MOR or AXSM?

Which has better valuation & earnings, MOR or AXSM?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Does the media favor RDY or MOR?

Which has better valuation & earnings, RDY or MOR?

Is RDY or MOR more profitable?

Do analysts prefer RDY or MOR?

Which has more volatility and risk, RDY or MOR?

Do institutionals and insiders have more ownership in RDY or MOR?

Summary

How does MorphoSys compare to Crinetics Pharmaceuticals?

Which has more risk & volatility, CRNX or MOR?

Does the media prefer CRNX or MOR?

Do institutionals and insiders hold more shares of CRNX or MOR?

Do analysts prefer CRNX or MOR?

Which has better earnings & valuation, CRNX or MOR?

Is CRNX or MOR more profitable?

Summary

How does MorphoSys compare to Lantheus?

Do insiders & institutionals believe in MOR or LNTH?

Which has better valuation and earnings, MOR or LNTH?

Which has more risk and volatility, MOR or LNTH?

Is MOR or LNTH more profitable?

Do analysts rate MOR or LNTH?

Does the media prefer MOR or LNTH?

Summary

How does MorphoSys compare to Belite Bio?

Which has more risk and volatility, MOR or BLTE?

Is MOR or BLTE more profitable?

Which has higher earnings & valuation, MOR or BLTE?

Do analysts recommend MOR or BLTE?

Do insiders & institutionals hold more shares of MOR or BLTE?

Does the media prefer MOR or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools